Spectrum Pharmaceuticals, Inc. (SPPI) - Financial and Strategic SWOT Analysis Review

Document Sample
Spectrum Pharmaceuticals, Inc. (SPPI) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					          Spectrum Pharmaceuticals, Inc. (SPPI) - Financial and Strategic SWOT
                                  Analysis Review
        Reference Code: GDPH112072FSA                                                                                            Publication Date: MAR 2013

          11500 South Eastern Ave., Suite 240,               Phone              +1 702 8356300                      Revenue          267.7 (million USD)
          Henderson, NV                                      Fax                +1 702 2607405                      Net Profit       94.55 (million USD)
          89052                                              Website            www.spectrumpharm.com               Employees        193
                                                                                                                                     Pharmaceuticals           &
          United States                                      Exchange           SPPI [NASDAQ]                       Industry
                                                                                                                                     Healthcare

       Company Overview
       Spectrum Pharmaceuticals, Inc., (Spectrum Pharmaceuticals), formerly known as NeoTherapeutics, Inc., is an integrated
       biotechnology company. It carries out the acquisition, development, and commercialization of diverse pipeline of late-stage
       clinical and commercial products with particular focus on oncology. The company markets three drugs, namely, FUSILEV,
       FOLOTYN and ZEVALIN. It has two drugs in late stage development, namely, apaziquone and belinostat and also has a
       diversified pipeline of novel drug candidates for various therapeutic categories. The company’s pipeline product portfolio
       comprises Ozarelix, Ortataxel, SPI-1620, Lucanthone, SPI-2012 and SPI-014.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Spectrum Pharmaceuticals, Inc., SWOT Analysis
         Dr. Rajesh C. Shrotriya             Chairman                                 Strengths                                Weaknesses
         Ken Keller                          Chief Operating Officer
                                                                                      Patents and Proprietary                  Limited Number of Customers
         Dr. Krishan K. Arora, Ph.D.         Director                                 Technology Portfolio
                                                                                                                               Dependence on Suppliers
         Stuart M. Krassner                  Director
                                                                                      Broad Product Portfolio
         Luigi Lenaz, M.D.                   Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                            Threats

       Share Data                                                                     Key Business Initiatives                 Intense Competition
         Spectrum Pharmaceuticals, Inc.
                                                                                      Growing Cancer Market                    Government Regulations
        Share Price (USD) as on 15-Mar-                                  7.76
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                        1.46        GlobalData
        Market Cap (million USD)                                         466
        Enterprise Value (million USD)                                   401
        Shares Outstanding (million)                                       60
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 18, 2013         Spectrum Pharma Appoints Lee Allen As CMO
                                                                                      Mar 12, 2013         Spectrum Pharma Provides Corporate Update
                                                                                      Feb 21, 2013         Spectrum Pharma            Reports   Revenue        Of
                                                                                                           $70.1m In Q4 2012
                                                                                      Jan 11, 2013         Spectrum Pharma Promotes Joseph Turgeon
                                                                                                           To Chief Commercial Officer
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData



       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Spectrum Pharmaceuticals, Inc. (SPPI) - Financial and Strategic                                                                  Reference Code: GDPH112072FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                         Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Spectrum Pharmaceuticals, Inc. - Key Facts ...................................................................................................................................... 5
       Spectrum Pharmaceuticals, Inc. - Key Employees ............................................................................................................................. 6
       Spectrum Pharmaceuticals, Inc. - Key Employee Biographies ........................................................................................................... 7
       Spectrum Pharmaceuticals, Inc. - Major Products and Services ........................................................................................................ 8
       Spectrum Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ........................................................................................ 9
          Spectrum Pharmaceuticals, Inc., Pipeline Products by Therapy Area ............................................................................................ 9
          Spectrum Pharmaceuticals, Inc., Pipeline Products by Development Phase................................................................................ 10
       Spectrum Pharmaceuticals, Inc. - History......................................................................................................................................... 13
       Spectrum Pharmaceuticals, Inc. - Company Statement ................................................................................................................... 16
       Spectrum Pharmaceuticals, Inc. - Locations And Subsidiaries......................................................................................................... 17
          Head Office ................................................................................................................................................................................... 17
          Other Locations & Subsidiaries ..................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 19
       Spectrum Pharmaceuticals, Inc. - Business Description .................................................................................................................. 19
       Spectrum Pharmaceuticals, Inc. - Corporate Strategy ..................................................................................................................... 20
       Spectrum Pharmaceuticals, Inc. - SWOT Analysis ........................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          Spectrum Pharmaceuticals, Inc. - Strengths ................................................................................................................................. 21
             Strength - Patents and Proprietary Technology Portfolio .......................................................................................................... 21
             Strength - Broad Product Portfolio ............................................................................................................................................ 21
             Strength - Sound Financial Performance .................................................................................................................................. 21
          Spectrum Pharmaceuticals, Inc. - Weaknesses ............................................................................................................................ 22
             Weakness - Limited Number of Customers ............................................................................................................................... 22
             Weakness - Dependence on Suppliers ..................................................................................................................................... 22
          Spectrum Pharmaceuticals, Inc. - Opportunities ........................................................................................................................... 22
             Opportunity - Key Business Initiatives ....................................................................................................................................... 22
             Opportunity - Growing Cancer Market ....................................................................................................................................... 22
             Opportunity - Emerging Markets ............................................................................................................................................... 23
          Spectrum Pharmaceuticals, Inc. - Threats .................................................................................................................................... 23
             Threat - Intense Competition ..................................................................................................................................................... 23
             Threat - Government Regulations ............................................................................................................................................. 23
             Threat - Technological Changes ............................................................................................................................................... 23
       Spectrum Pharmaceuticals, Inc. - Key Competitors ......................................................................................................................... 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30


Spectrum Pharmaceuticals, Inc. (SPPI) - Financial and Strategic                                                                                              Reference Code: GDPH112072FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ......................................... 30
          Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ......................................... 31
       Spectrum Pharmaceuticals, Inc., Recent Deals Summary ............................................................................................................... 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          Spectrum Pharmaceuticals, Inc., Recent Developments .............................................................................................................. 33
             Mar 18, 2013: Spectrum Pharma Appoints Lee Allen As CMO ................................................................................................. 33
             Mar 12, 2013: Spectrum Pharma Provides Corporate Update .................................................................................................. 33
             Feb 21, 2013: Spectrum Pharma Reports Revenue Of $70.1m In Q4 2012 ............................................................................. 34
             Jan 11, 2013: Spectrum Pharma Promotes Joseph Turgeon To Chief Commercial Officer...................................................... 35
             Dec 13, 2012: Spectrum Pharma Announces Presentation Of Zevalin, Folotyn And Belinostat Clinical Data At 54th Annual
             Meeting Of ASH ..................
				
DOCUMENT INFO
Description: Spectrum Pharmaceuticals, Inc., (Spectrum Pharmaceuticals), formerly known as NeoTherapeutics, Inc., is an integrated biotechnology company. It carries out the acquisition, development, and commercialization of diverse pipeline of late-stage clinical and commercial products with particular focus on oncology. The company markets three drugs, namely, FUSILEV, FOLOTYN and ZEVALIN. It has two drugs in late stage development, namely, apaziquone and belinostat and also has a diversified pipeline of novel drug candidates for various therapeutic categories. The company’s pipeline product portfolio comprises Ozarelix, Ortataxel, SPI-1620, Lucanthone, SPI-2012 and SPI-014.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.